Table 2.

Patients

	N = 534
Demographics
Age, Median (IQR)	6.0 (3.0, 12.0)
Sex (male), N (%)	281 (52.6)
Race, N (%)
White	354 (66.3)
Black	68 (12.7)
Asian	17 (3.2)
Other	95 (17.8)
Medicaid insurance, N (%)	214 (40.1)
Hospital Region, N (%)
Northeast	92 (17.2)
Southeast	90 (16.9)
Southwest	60 (11.2)
Midwest	156 (29.2)
West	136 (25.5)
Clinical Features and Medication Exposures
Length of stay in days, Median (IQR)	6.0 (4.0, 9.0)
ICU level of care, N (%)	42 (7.9)
Macrophage activation syndrome*, N (%)	63 (11.8)
Glucocorticoids, N (%)	309 (57.9)
Biologics^, N (%)	156 (29.2)
Anakinra, N (%)	137 (25.7)
Canakinumab, N (%)	11 (2.1)
Tocilizumab, N (%)	20 (3.7)
Methotrexate, N (%)	41 (7.7)
Scheduled NSAIDs, N (%)	452 (84.6)
Readmission ≤ 90 days after discharge#, N (%)	75 (14.0)

^*Based on discharge ICD CM code. Diagnosis of MAS may have occurred at any point during hospitalization.

^{^}Not mutually exclusive. 9 patients received both canakinumab and anakinra and 3 patients received both anakinra and tocilizumab during hospitalization.

^#All-cause readmissions.